Description

Arylomycin A2, an antibiotic (Antibiotic), is a lipopeptide type I signal peptidase (SPase I) inhibitor. Arylomycin A2 has antibacterial effects[1].—COVID-19-immunoregulation–C42H60N6O11—-[1]Mark Paetzel, et al. Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor. J Biol Chem. 2004 Jul 16;279(29):30781-90. |[2]Katrijn Bockstael, et al. Evaluation of the type I signal peptidase as antibacterial target for biofilm-associated infections of Staphylococcus epidermidis. Microbiology (Reading). 2009 Nov;155(Pt 11):3719-3729.–459844-20-3–824.96—-O=C([C@H]1NC([C@H](C)NC([C@@H](N(C)C(CNC([C@@H](C)NC([C@@H](CO)N(C)C(CCCCCCCCC(C)C)=O)=O)=O)=O)C2=CC=C(C(C3=CC(C1)=CC=C3O)=C2)O)=O)=O)O–Infection–10 mM in DMSO–Antibiotic;Bacterial–Lipopeptide–Anti-infection–Peptides